**Altered medial prefrontal cortex and dorsal raphé activity predict genotype and correlate with abnormal learning behaviour in a mouse model of autism-associated 2p16.3 deletion**

Short title: *Nrxn1α* impacts on cognition and brain function

Rebecca B Hughes1, Jayde Whittingham-Dowd1, Steven J Clapcote2, Susan J Broughton1, Neil Dawson1.

1. Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, LA1 4YQ, UK.
2. School of Biomedical Sciences, University of Leeds, Leeds, LS2 9JT, UK.

**Corresponding author:** Dr Neil Dawson, Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, LA1 4YQ. Email: [n.dawson1@lancaster.ac.uk](mailto:n.dawson1@lancaster.ac.uk).

**Acknowledgements**

Dr. Hughes received support in the form of a Lancaster University Faculty of Health and Medicine (FHM) PhD studentship to support this work, awarded to Dr. Dawson and Dr. Broughton. The work was also supported by funding from The Royal Society (RG140134) awarded to Dr. Dawson. The other authors received no specific funding for this work. Dr. Hughes, Dr. Whittingham-Dowd, Dr. Clapcote, Dr. Broughton and Dr. Dawson report no biomedical financial interests or potential conflicts of interest.

**Abstract**

2p16.3 deletion, involving *NEUREXIN1* (*NRXN1*) heterozygous deletion, substantially increases the risk of developing autism and other neurodevelopmental disorders. We have a poor understanding of how *NRXN1* heterozygosity impacts on brain function and cognition to increase the risk of developing the disorder. Here we characterise the impact of *Nrxn1α* heterozygosity on cerebral metabolism, in mice, using 14C-2-deoxyglucose imaging. We also assess performance in an olfactory-based discrimination and reversal learning task (OB-DaRL) and locomotor activity. We use decision tree classifiers to test the predictive relationship between cerebral metabolism and *Nrxn1α* genotype. Our data show that*Nrxn1α* heterozygosity induces prefrontal cortex (medial prelimbic cortex, mPrL) hypometabolism and a contrasting dorsal raphé nucleus (DRN) hypermetabolism. Metabolism in these regions allows for the predictive classification of *Nrxn1α* genotype. Consistent with reduced mPrL glucose utilisation, prefrontal cortex insulin receptor signalling is decreased in *Nrxn1α+/-* mice. Behaviourally, *Nrxn1α*+/- mice show enhanced learning of a novel discrimination, impaired reversal learning and an increased latency to make correct choices. In addition, male *Nrxn1α*+/- mice show hyperlocomotor activity. Correlative analysis suggests that mPrL hypometabolism contributes to the enhanced novel odour discrimination seen in *Nrxn1α+/-* mice, while DRN hypermetabolism contributes to their increased latency in making correct choices. The data show that *Nrxn1*α heterozygosity impacts on prefrontal cortex and serotonin system function, which contribute to the cognitive alterations seen in these animals. The data suggest that *Nrxn1α+/-* mice provide a translational model for the cognitive and behavioural alterations seen in autism and other neurodevelopmental disorders associated with 2p16.3 deletion.

**Lay Summary**

Deletion of the chromosomal region 2p16.3, involving reduced *NEUREXIN1* gene expression, dramatically increases the risk of developing autism. Here we show that reduced *Neurexin1α* expression, in mice, impacts on the prefrontal cortex and impairs cognitive flexibility. The data suggest that 2p16.3 deletion increases the risk of developing autism by impacting on the prefrontal cortex. Mice with the deletion are a useful model for testing new drugs to treat the cognitive flexibility problems experienced by people with autism.

**Keywords**: copy number variation/copy number variants (CNV), mouse models, cognitive neuroscience, imaging genetics, serotonin, genotype-phenotype correlation, frontal lobe

1. **Introduction**

Copy number variants (CNVs) are strongly implicated in the genetic aetiology of autism and other neurodevelopmental disorders. Population-based studies show that 2p16.3 deletions (OMIM #614332), involving heterozygous NEUREXIN1 (NRXN1) gene deletion, are associated with developmental delay, learning difficulties, and a substantially increased risk of developing autism spectrum disorder (ASD, odds ratio = ~14.9, Matsunami et al., 2013; Wang et al., 2017; Yuen et al., 2017). Individuals with NRXN1 deletions also show symptoms of attention deficit hyperactivity disorder (ADHD, Ching et al., 2010; Schaaf et al., 2012), obsessive compulsive disorder (OCD) (Castronovo et al., 2020) and are at increased risk of developing Tourette’s syndrome (TS, odds ratio = ~20.3, Huang et al., 2017) and schizophrenia (ScZ, odds ratio = ~14.4, Marshall et al., 2017). Most NRXN1 deletions localize to the promoter and initial exons of NRXN1α, leaving the NRXN1β coding sequence intact, and are thus predicted to impact on NRXN1α but not NRXN1β transcripts (Reichelt et al., 2012).

Rodent translational studies have been dedicated to elucidating the behavioural consequences of Nrxn1α deficiency, to establish if this results in phenotypes relevant to ASD and the other neurodevelopmental disorders associated with 2p16.3 deletion. Adult Nrxn1α homozygous knockout (KO) mice show decreased sociability, increased anxiety-like behaviour (Grayton et al., 2013) and a deficit in prepulse inhibition (PPI, Etherton et al., 2009), mirroring that seen in people with ASD (Cheng et al., 2018), ScZ (Braff et al., 1999) and TS (Swerdlow et al., 2001). Studies conducted across early development have identified deficits in ultrasonic vocalisations (USVs) and developmental milestones in *Nrxn1* KO mice, with some observations being sex-specific (Armstrong et al., 2020). As NRXN1 deletions in ASD, ScZ and TS are commonly heterozygous, other studies have focused on characterising Nrxn1α heterozygous (Nrxn1α+/−) mice, reporting sex-dependent alterations in novelty responsiveness (Laarakker et al., 2012) and memory deficits (Dachtler et al., 2015). Nrxn1α+/− mice also show deficits in social memory, while effects on sociability appear to be limited (Grayton et al., 2013; Dachtler et al., 2015). Emerging evidence suggests that the impact of *Nrxn1α* heterozygosity on cognition may be domain specific and may involve abnormally enhanced as well as impaired cognition, including enhanced motor learning (Hughes et al., 2020). Despite these observations in relatively simple tests, the potential impact of *Nrxn1α* heterozygosity on discrimination/associative learning and cognitive flexibility has not been assessed. This is surprising given the altered discrimination learning (Plaisted et al., 1998), associative learning (Brambilla et al., 2011; Eordegh et al., 2020) and cognitive flexibility, including reversal learning (Crawley et al., 2020; Lange et al., 2017; Schlagenhauf et al., 2014), reported in neurodevelopmental disorders associated with 2p16.3 deletion.

Our previous study has identified alterations in functional brain network connectivity in *Nrxn1α+/-* mice that have translational relevance to those seen in neurodevelopmental disorders associated with 2p16.3 deletion (Hughes et al., 2020). How alterations in brain function relate to altered behaviour in *Nrxn1α+/-* mice is yet to be characterised. In addition, we do not know how *Nrxn1α* heterozygosity in mice impacts on associative and reversal learning. Therefore, in this study we characterise the performance of *Nrxn1α+/-*mice in an odour-based discrimination and reversal learning (OB-DaRL) task and characterise cerebral metabolism in the same animals using 14C-2-deoxyglucose (14C-2-DG) functional brain imaging, a translational analogue of 18F-2-deoxyglucose positron emission tomography (18F-FDG PET) functional brain imaging routinely applied in humans. In addition, we assess the impact of *Nrxn1α* heterozygosity on locomotor and anxiety-like behaviour in the open-field test (OFT).

1. **Methods**

**2.1 Animals**

Full animal details can be found in Dacthler et al. (2015), and the generation of the mice is detailed in Missler et al. (2003). Male B6;129-Nrxn3tm1Sud/Nrxn1tm1Sud/Nrxn2tm1Sud/J mice (The Jackson Laboratory, Stock ID: #006377) were purchased as heterozygous KO at Nrxn1, homozygous KO at Nrxn2, and wild-type (WT) at Nrxn3 and backcrossed twice onto the C57BL/6NCrl strain (Charles River, Margate, UK) to obtain mice selectively heterozygous for Nrxn1α (i.e. heterozygous KO at Nrxn1α and WT at both Nrxn2 and Nrxn3). Experimental animals (Nrxn1α+/− and WT littermates, aged 12–24 weeks) were generated through cousin mating. For *Nrxn1α* genotyping, the primers 5’-CTG ATG GTA CAG GGC AGT AGA GGA CCA-3’ (common forward), 5’-CGA GCC TCC CAA CAG CGG TGG CGG GA-3’ (WT reverse) and 5’-GAG CGC GCG CGG CGG AGT TGT TGA C-3’ (KO reverse) were used with HotShot Diamond (Clent Life Science, United Kingdom) using a thermocycling program of: 95°C for 5 min, followed by 35 cycles of 94°C for 30 secs, 70°C for 30 secs, and 72°C for 30 secs followed by a 72°C for 2 minutes step. PCR products were visualized using agarose gel electrophoresis, with a 440-bp band indicating the wild-type (WT) allele and a 390-bp band indicating the KO allele. Animal genotype was determined from an identifying ear notch taken at weaning age and confirmed from a separate tissue sample taken at sacrifice. Animals were group housed (4–6/cage) under standard conditions (individually ventilated cages, 21°C, 45–65% humidity, 12h:12h dark/light cycle, lights on at 07:00) with food and water access *ad libitum*. To motivate animals to perform in the OB-DaRL task, where animals have to dig for a 14mg sucrose reward pellet (TestDiet, St. Louis, MO, USA), mice were food restricted from 14 days prior to the start of the task until the end of the experiment. To allow the close monitoring of food consumption animals were singly housed during restriction. Animals were given standard laboratory chow (Teklad maintenance diet, Envigo) and restricted to 80-85% of their free-feeding weight. Body weight and body condition score (Ullman-Cullere and Foltz, 1999) were monitored 5 days a week. Behavioural experiments were conducted during the light phase. Experiments were carried out in compliance with the UK Animals (Scientific Procedures) Act, 1986 Amendment Regulations (SI 2012/3039) and approved by the Lancaster University Animal Welfare and Ethics Review Board (AWERB).

**2.2 Open Field Test (OFT)**

Locomotor activity (LMA) and anxiety-like behaviours during exposure to a novel environment were recorded by placing the animals into white Perspex circular open field arenas (38cm diameter) and video recording behaviour for 15 minutes. Arenas were cleaned with 70% ethanol prior to and after each run. Automated tracking software (Ethovision XT v8.5, Noldus) was used to determine measures of LMA (distance moved (cm), average velocity (cm/s) and movement duration and frequency) and anxiety-like behaviour (central zone (15cm diameter) duration (secs) and frequency). Group sizes were WT: *n*=36 (male, *n*=18) and Nrxn1α+/−: *n* = 33 (male, *n*=15).

**2.3 Odour-based Discrimination and Reversal Learning (OB-DaRL) Task**

A detailed overview of the OB-DaRL task methodology is provided in the supplemental information, with the procedure adapted from published work in rats (Birrell and Brown, 2000; Dawson et al., 2012) and mice (Young et al., 2010; Tanaka et al., 2011). In brief, animals went through a series of task stages; *phase 1*: habituation and learning to dig, *phase 2*: odour habituation and novel odour discrimination, *phase 3*: a second odour discrimination and reversal learning. During *phase 1* animals learn to dig in sand in order to retrieve sucrose pellet rewards. In *phase 2,* animals were habituated to each odour (spices in sand, two odour bowls per trial, presented sequentially). Then animals undertake a novel odour discrimination (Discrimination 1), where they learn that only one of the two odours presented is rewarded. No reversal-learning stage was applied following this initial discrimination. Instead, animals proceeded to *phase 3*, in which mice were presented with a new odour pair and learned the second odour-reward discrimination (Discrimination 2). The animal then moved to the reversal-learning stage, where the previously unrewarded odour within the odour pair used during Discrimination 2 was now rewarded, and vice versa. At each stage, the animal was judged to have learned the discrimination/reversal when it had performed six consecutive correct choices. This criterion is aligned with that applied in previous studies (Birrell and Brown, 2000; Dawson et al., 2012; Young et al., 2010; Tanaka et al., 2011). There is a 1.56% chance of animals performing six consecutive correct choice trials by random choice selection. At each phase, correct and incorrect trial choices, trials to criteria (TTC) and the latency to dig were recorded. In addition, the correction ratio, the proportion of trials that were correct choices made after a previously punished (exclusion from reward collection and a time out) incorrect trial was calculated. Group sizes were WT: *n*=29 (male, *n*=16) and *Nrxn1α+*/−: *n*=26 (male, *n*=13).

**2.4 14C-2-deoxyglucose (14C-2-DG) Functional Brain Imaging**

14C-2-DG functional brain imaging was conducted in accordance with published protocols (Hughes et al., 2020; Openshaw et al., 2020). The method used allows the determination of Local cerebral glucose utilisation (LCGU) in unanesthetised, awake and freely-moving mice. LCGU was determined in 39 brain regions of interest (RoI) across a range of neural systems (supplemental information: Table S2), from autoradiographic images using a computer-based image analysis system (MCID/M5+, Interfocus) with reference to a stereotaxic mouse brain atlas (Paxinos and Franklin, 2001). The experimenter undertaking the analysis was blind to the sex and genotype of the animals. Group sizes were WT: n = 19 (male, n = 9) and Nrxn1α+/−: n = 20 (male, n = 10). Further detail is provided in the supplementary information.

**2.5 Insulin Receptor Signalling Characterisation Using Western Blotting**

Given the reduce glucose utilization we identified in the mPFC of *Nrxn1α*+/- mice, and the reduced PFC insulin signalling (Zhao et al., 2006) and insulin resistance (Manco et al., 2021) seen in disorders associated with 2p16.3 deletion, we used Western blotting to characterize insulin receptor signalling in the PFC and hippocampus of *Nrxn1α*+/- mice (WT: n=6 [male, n=3]; *Nrxn1α*+/-: n=8 [male, n=4]). The primary antibodies were for the insulin receptor (beta subunit: IRβ, Merck Millipore, Cat. No. 07-724, 1:1000) and the phosphorylated/activated insulin receptor (tyrosine 972 phosphorylated, IR pTyr972/pIR, Merck Millipore, Cat. No. 07-838, 1:1000). The secondary antibody was a goat anti-rabbit IgG, HRP-linked Antibody (Cell Signalling, Cat. No. 7074S, 1:2000). Images were acquired with the Chemi-Doc MP system and analyzed using Image Lab (Bio-Rad Laboratories Ltd), with normalization to total protein load. Data were then normalized to same-sex WT control. Full details are provided in the supplemental information.

**2.6 Predicting *Nrxn1α* Genotype from 14C-2-deoxyglucose Functional Brain Imaging Data using Decision Tree Classification**

Decision tree classifiers, based on the classification and regression trees (CART) algorithm, are a supervised machine learning approach that builds a classifier from a set of training samples with a list of known features and known class labels. In terms of our data, the class label was genotype (WT or Nrxn1α+/−) and the features measurements was LCGU in 39 RoI. The decision trees can then be used to predict the classification of unknown “test” cases. The trees also provide information on which features are most useful in the classification, and provide threshold values that the algorithm uses to perform the classification. To determine the parameters that resulted in optimal tree performance, we characterised the ability of the trees to classify unseen data in terms of accuracy (the ability to correctly classify animals), sensitivity (the ability to correctly classify true positives, i.e. *Nrxn1α+/−* mice) and specificity (the ability to correctly classify true negatives, i.e. WT mice) using a leave-one-out cross validation (LOOCV) strategy. We then tested the ability of these trees to correctly classify mice from an independently generated test set involving 8 WT (male n=4) and 6 Nrxn1α+/− (male n=3) mice. Performance was assessed in terms of accuracy, precision (the ability of the classifier not to mislabel a case) and specificity. Scikit-learn ([https://sklearn.org](https://sklearn.org/), Pedregosa et al., 2011) was used to undertake decision tree classification. Further detail is included in the supplemental information.

**2.7 Statistical Analysis**

Data were statistically analysed in R (<https://www.R-project.org/>). OFT data were analysed using repeated measures ANOVA with sex and genotype as independent variables and time bin as the within subjects variable. Where significant sex x genotype interactions were observed, data from each sex were analysed separately using repeated measures ANOVA. OB-DaRL task and 14C-2-DG data were analysed using ANOVA, with sex and genotype as independent variables. For genotype effects in the 14C-2-DG data we report both the unadjusted p-value from the ANOVA, and the p-value adjusted using *post-hoc* Benjamini-Hochberg correction for multiple comparisons on the basis of comparing 39 brain RoI. Western blot data were analysed using Wilcoxon test. The relationship between LCGU and behavioural parameters was analysed using Pearson’s correlation coefficient. Significance was set at p<0.05.

1. **Results**

**3.1 *Nrxn1α* heterozygosity increases anxiety-like behaviour in mice of both sexes and induces a mild hyperactivity selectively in male mice**

When exposed to a novel open field environment, Nrxn1α+/− mice showed increased anxiety-like behaviour, evidenced by less time spent in the arena central zone (Figure 1, F(1,960)=16.72, p<.001). By contrast, the frequency with which the animals entered the central zone was not different between genotypes (F(1,974)=0.19, p=.664). There was no evidence that sex influenced the impact on *Nrxn1α* heterozygosity on time spent in the central zone (F(1,960)=0.01, p=.906). In addition, male Nrxn1α+/− mice showed a mild hyperactivity when exposed to the novel open field environment, while female mice did not. A significant sex x genotype interaction was found for both distanced travelled (F(1,974) = 12.50, p<.001). Male Nrxn1α+/− mice showed an increased distanced travelled (15% increase, F(1,464)=14.99, p<.001) in comparison to male WTs. By contrast, female Nrxn1α+/− mice showed a similar distanced travelled (F(1,509)=1.00, p=.317) to female WT controls. While the hyperlocomotor activity seen in male Nrxn1α+/− mice appeared to be more evident during early of time bins of the OFT, we found no evidence for a significant interaction between time bin and genotype for distance travelled (F(14,464)=1.07, p=.381). Therefore, there was no evidence that the increased activity was limited to specific time point during the OFT. A similar effect was seen for movement duration (sex x genotype, F(1,974)=11.22, p<.001), with Nrxn1α+/− males (8% increase, F(1,464)=11.16, p<.001) but not females (F(1,509)=1.42, p=.234) being significantly different from same-sex WTs. Again, in males there was no significant interaction between genotype and time bin for movement duration (F(14,464)=0.99, p=.464), indicating that the increased activity was not limited a specific time point during the OFT. By contrast, there was no evidence that *Nrxn1*α heterozygosity impacted on movement frequency, in mice of either sex (supplementary information, Figure S1). These data show that *Nrxn1α* heterozygosity induces a mild hyperactivity selectively in males, in part by impacting on movement duration while not modifying the frequency at which movements are initiated.

**3.2 *Nrxn1α* heterozygosity enhances learning of a novel odour-based discrimination but impairs reversal learning**

In the OB-DaRL task Nrxn1α+/− mice required fewer trials to reach criterion (TTC) during the first odour discrimination (Figure 2, Discrimination 1: F(1,47)=5.74, p=.021), indicating enhanced learning of this novel odour-reward association. However, when presented with the second odour pair, Nrxn1α+/− mice performed at a similar level to WTs (Discrimination 2: TTC, F(1,56)=0.16, p=.694). There was no evidence that the impact of *Nrxn1α* heterozygosity was influenced by sex for either discrimination (sex x genotype; Discrimination 1: F(1,47)=0.18, p=.673; Discrimination 2: F(1,56)=0.57, p=.454).

During the initial discrimination Nrxn1α+/− mice took significantly longer to complete trials than WTs when making correct (trial latency; Discrimination 1: F(1,48)=7.69, p=.008) but not incorrect (F(1,48)=1.94, p=.170) choices. This genotype effect was also evident in the second odour discrimination (Discrimination 2, correct: F(1,53)=4.60, p=.037, incorrect: F(1,49)=2.04, p=.160). There was no evidence that the genotype difference in correct choice response latency was influenced by sex (Discrimination 1: F(1,48)=0.20, p=.657; Discrimination 2, F(1,53)=0.36, p=.550). The mild hyperactive phenotype identified in male Nrxn1α+/− mice could potentially contribute to the increased correct response latency seen, although this is unlikely to be the case for the increased latency seen in female Nrxn1α+/− mice, as they do not show this hyperactivity. We found no correlation between locomotor activity levels in the open field, as measured by distance travelled, and correct trial latency during Discrimination 1 (r= 0.10, p=.491) or Discrimination 2 (r= -0.11, p=0.481), suggesting that correct trial latency is not strongly related to locomotor activity levels. This suggests that the mild hyperactivity phenotype seen in male Nrxn1α+/− mice is unlikely to be driving the increased correct trial latency seen in these animals.

In the reversal learning phase Nrxn1α+/− mice required significantly more TTC (F(1,47)=4.21, p=.046) than WT mice, supporting a deficit in reversal learning. There was no evidence that this deficit was influenced by sex (TTC, F(1,47)=1.46, p=.233). To determine whether this deficit was due to an altered sensitivity to punishment we characterised the correction ratio (Figure 2). We found no evidence to support a difference in the correction ratio between Nrxn1α+/− and WT mice in the reversal phase (F(1,45)=1.88, p=.177). This was also true for the first (F(1,38)=0.15, p=.704) and second (F(1,45)=2.03, p=.161) odour discrimination (supplementary information, Figure S2). These data support a similar sensitivity to punishment in Nrxn1α+/− mice.

We found no evidence to suggest that performance during the reversal learning stage of the task, in terms of TTC, was significantly correlated with performance during learning the odour discrimination in Discrimination 2. In this way TTC in the reversal stage did not correlate with TTC (r = 0.19, p=.243) or trial response latencies (correct [r = 0.22, p=.166] or incorrect [r =0.07, p=.660]) in Discrimination 2. This suggests that any increase in odour exposure during Discrimination 2 that results from the increased correct trial latency seen in Nrxn1α+/− mice is unlikely to contribute to their altered performance in the reversal learning stage.

**3.3 Cerebral metabolism in the prefrontal-mesolimbic system and dorsal raphé predicts *Nrxn1α* heterozygosity**

Nrxn1α+/− mice showed hypometabolism in the medial prelimbic cortex (mPrL: F(1,31)=10.73, p=.003 unadjusted, p=.049 Benjamini-Hochberg corrected, 95% CI [-0.14, -0.03]) with a contrasting hypermetabolism in the dorsal raphé nucleus (DRN: F(1,31)=14.56, p<.001 unadjusted, p=.024 Benjamini-Hochberg corrected, 95% CI [0.034, 0.1549], Figure 3). There was no evidence that sex modified the impact of *Nrxn1α* heterozgosity on cerebral metabolism in these regions (sex x genotype; mPrL: F(1,31)=0.47, p=.500; DRN: F(1,31)=0.04, p=0.84). Full 14C-2-DG data are shown in the supplemental information (Table S2).

We used decision tree classification to establish the validity of regional cerebral metabolism in predicting *Nrxn1α* genotype. Initial validation studies, employing LOOCV, identified decision trees with a depth of 2, using the Gini impurity index (a measure of sample impurity at each node), as the most useful in classifying *Nrxn1α* genotype using the brain imaging data. These decision trees had an accuracy of 79%, a specificity of 68% and a sensitivity of 90% in classifying Nrxn1α+/− from WT mice, when classifying the excluded case from LOOCV.

The decision trees most commonly seen in the LOOCV analysis (56%) featured the mPrL at the root (level 1) and the nucleus accumbens shell (NaS) at level two. The next most common decision trees involved NaS at the root (level 1) and the mPrL at level 2 (18%, Figure 3). The finding that mPrL metabolism can be used to classify *Nrxn1α* genotype is consistent with the mPrL hypometabolism seen in Nrxn1α+/− mice. However, there was no evidence for a significant difference in NaS metabolism between the genotypes, at the group level (F(1,31)=2.82, p=.103). As the NaS most commonly featured at level 2 of the decision trees, this suggests that metabolism in this region is useful in differentiating a subset of Nrxn1α+/− from WT mice, for example once mPFC metabolism has been taken into account. Alternatively, this may suggest that the NaS is dysfunctional in a subset of Nrxn1α+/− mice. To test this we selectively analysed genotype significance in a subset of animals when mPFC metabolism had been taken into account. As the decision trees indicated that a mPFC 14C-2-DG uptake ratio >1.153 is associated with being WT (Figure 3), we analysed group-level genotype differences in NaS metabolism in mice with a mPFC 14C-2-DG uptake ratio <=1.153. We found evidence for NaS hypometabolism in this subgroup of Nrxn1α+/− mice (F(1,20)=5.62, p=.028, WT: n=9, Nrxn1α+/−: n=19). This is consistent with the observation that a NaS 14C-2-DG uptake ratio <0.773 is useful in classifying Nrxn1α+/− from WT mice, once mPrL metabolism has been considered (Figure 3). The next most common structure (13%) seen in the LOOCV decision trees involved the DRN at the root (level 1), with a DRN 14C-2-DG uptake ratio <=0.728 being indicative of the WT genotype. This is consistent with the significant DRN hypermetabolism found in Nrxn1α+/− mice.

To further validate these decision trees we tested their ability to classify mice from an independently generated test set. For this test data, decision trees containing the mPrL (level 1) and NaS (level 2) performed well in classify Nrxn1α+/− from WT mice (accuracy: 79-93%, precision: 71-83%, specificity: 83-100%). Decision trees involving the DRN at level 1 also performed well (accuracy: 71-100%, precision: 83%, specificity: 62%). See the supplemental information for a detailed overview.

These data show that the mPrL and DRN are dysfunctional in Nrxn1α+/− mice, and that metabolism in these regions, along with that in the NaS, are useful in predicting Nrxn1α genotype.

**3.4 Insulin receptor signalling is reduced in the PFC, but not in the hippocampus, of Nrxn1α+/− mice**

We found evidence supporting insulin resistance in the PFC of *Nrxn1α+/-* mice, consistent with the decreased mPrL glucose utilisation present in these animals (Figure 3, supplemental information: Table S2). Both total IR (IRβ, p=0.033) and phosphorylated/activated IR (pIR: p=.047) levels were reduced in the PFC of *Nrxn1α*+/- mice. The ratio between pIR and IRβ was also reduced (p=.019). This supports both reduced IR expression and reduced IR activation in the PFC of *Nrxn1α*+/- mice. By contrast, IRβ and pIR levels, and the pIR:IRβ ratio, were not altered in the hippocampus of *Nrxn1α*+/- mice, consistent with the unaltered hippocampal glucose utilization seen in these animals (supplemental information: Table S2 and Figure S3).

**3.5 Constitutive cerebral metabolism in the mPFC and dorsal raphé correlates with measures of locomotor activity and odour-reward discrimination learning in mice**

To further understand the relationship between the altered cerebral metabolism and behaviour seen in Nrxn1α+/− mice we undertook correlative analysis. Given the altered metabolism seen in the mPrL and DRN, we analysed correlations between metabolism in these regions and the behavioural parameters found to be altered in Nrxn1α+/− mice.

Cerebral metabolism in the mPrL negatively correlated with measures of LMA (distance moved: r=-0.49, p=.033; velocity: r=-0.49, p=.033, movement duration: r=0.47, p=0.04) in male mice. These correlations were not seen in female mice (distance moved: r=-0.13, p=0.62; velocity: r=-0.12, p=.647; movement duration: r=-0.06, p=.820, Figure 4). There was no evidence that DRN metabolism correlates with LMA (supplemental information: Table S3 and S4). This suggests that mPrL metabolism negatively correlates with LMA in male but not female mice. Thus the mPrL hypometabolism seen in Nrxn1α+/− mice may contribute to the hyperlocomotor activity that is selectively seen in male Nrxn1α+/− mice.

Metabolism in the mPrL positively correlated with the number of trials required to learn a novel odour discrimination (Discrimination 1, TTC, r=0.48, p=.007). This suggests that the mPrL hypometabolism seen in Nrxn1α+/− mice may contribute to their enhanced performance in this phase of the task. By contrast, DRN metabolism did not correlate with TTC during this phase (r=-0.22, p=.255). However, DRN metabolism did positively correlate with response latency for making correct choices during this phase (r=0.38, p=.030). Therefore, the DRN hypermetabolism seen in Nrxn1α+/− mice may relate to the longer latency to make correct choices seen in these animals. By contrast, mPrL metabolism did not correlate with correct choice latency during this phase of the task (r=-0.09, p=.602).

For the reversal phase of the task, there was no correlation between metabolism in the mPrL (r=-0.24, p=.222) or DRN (r=-0.04, p=.835) with TTC. This suggests that the altered metabolism seen in these regions may not relate to the reversal learning deficits seen in Nrxn1α+/− mice. Full data are shown in the supplemental information (supplemental information: Tables S3 and S4).

1. **Discussion**

Our data show that *Nrxn1α* heterozygosity results in a deficit in reversal learning and abnormally enhanced learning of a novel odour-based discrimination that may have relevance to the core cognitive dysfunction seen in ASD and other neurodevelopmental disorders associated with 2p16.3 deletion. In addition, we show a sex-specific impact of *Nrxn1α* heterozygosity on LMA, with effects being more pronounced in males. This is consistent with published data reporting sex differences in the behavioural impact of *Nrxn1α* deletion (Armstrong et al., 2020; Grayton et al., 2013; Laarakker et al., 2012; Dachtler et al., 2015) and the more pronounced symptomatology of disorders associated with 2p16.3 deletion, such as ASD, in males. We also show that *Nrxn1α* heterozygosity impacts on mPFC and DRN function, with metabolism in these regions being predictive of *Nrxn1α* genotype. In addition, metabolism in these regions correlates with the behavioural differences seen in *Nrxn1α*+/- mice. Overall, these data suggest that *Nrxn1α*+/- mice provide a useful translational model for further understanding the mechanisms through with 2p16.3 deletion impacts on the brain to increase the risk of ASD and other neurodevelopmental disorders. Moreover, this animal model provides a useful tool for validating novel treatments for the cognitive and behavioural symptoms experienced by individuals with 2p16.3 deletion, and neurodevelopmental disorders associated with the CNV.

**4.1 The behavioural deficits seen in *Nrxn1α+/-* mice have translational relevance to those seen in neurodevelopmental disorders associated with 2p16.3 deletion**

*Nrxn1α* heterozygosity in mice induces phenotypes that have translational relevance to those seen in individuals with 2p16.3 deletions and disorders associated with this CNV, including ASD. The abnormally enhanced learning of a novel odour-reward discrimination in *Nrxn1α+/-* mice may have relevance to the enhanced abilities for stimulus discrimination (O’Riordan et al., 2006), and enhanced discrimination of novel stimuli (Plaisted et al., 1998, Edmondson et al., 2020), reported in individuals with ASD. However, it should be noted that these have primarily been characterised in terms of sensitivity to visual and auditory stimuli in ASD, whereas here were reporting the effect on olfactory discrimination. Determining if visual or auditory discrimination is also enhanced in *Nrxn1α+/-* mice, for example though use of the visual discrimination and reversal learning touchscreen task (Bussey et al., 2012), would be of interest. Nevertheless, the observation of enhanced a novel odour-based discrimination in *Nrxn1α*+/- mice is consistent with reports of enhanced learning, in terms of motor learning, as a consequence of *Nrxn1α* heterozygosity (Hughes et al., 2020) and knockout (Etherton et al., 2009). By contrast, there are also reports of impaired learning, in social (Dacthler et al., 2015) and novel object (Laarakker et al., 2012) recognition in *Nrxn1α* mutant mice. This suggests that the altered learning induced by *Nrxn1α* heterozygosity is domain specific, with both enhanced and impaired learning evident based on the type of learning and memory being measured. Further characterisation is needed to fully understand the basis of altered cognition induced by *Nrxn1α* heterozygosity and its translational alignment to 2p16.3 deletion in humans. The observation that *Nrxn1α+/-* mice require a similar number of trials to learn the second odour discrimination to WT mice suggests that their enhanced performance during the first odour discrimination relates to an enhanced ability to learn the contextual basis of the novel discrimination, rather than an enhanced ability to learn to discriminate between odour stimuli *per se.* As our study is the first reporting enhanced discrimination of a novel odour discrimination and a reversal learning deficit in *Nrxn1α* heterozygous mice, future studies confirming these cognitive deficits in other laboratories would be of interest.

In contrast to the enhanced novel discrimination learning, reversal learning was impaired in *Nrxn1α*+/- mice. This has translational relevance to the reversal learning deficit seen in neurodevelopmental disorders associated with 2p16.3 deletion, including that in ASD (Crawley et al., 2020), ScZ (Schlagenhauf et al., 2014; Reddy et al., 2016), and TS (Shephard et al., 2016). However, while these studies generally indicate perseveration and/or a lack of sensitivity to feedback as key mechanisms in the reversal learning deficit seen in these disorders (Crawley et al., 2020; Reddy et al., 2016), we found that sensitivity to punishment/feedback was not impaired in *Nrxn1α*+/- mice. Thus, alternative mechanisms may underlie the reversal learning deficit seen in *Nrxn1α+/-* mice. Given that set-shifting deficits are also seen in disorders associated with 2p16.3 deletion (Jazbec et al., 2007; Westwood et al., 2016), future studies aimed at characterising this potential deficit in *Nrxn1α*+/- mice would also be of translational interest.

Consistent with previous data (Laarakker et al., 2012), we identified hyperlocomotor activity when exposed to a novel environment selectively in male *Nrxn1α*+/- mice, However, these effects are not always found (Dachtler et al., 2015), and a contrasting hypoactivity has been reported in *Nrxn1α* KO mice (Grayton et al., 2013). This suggests that gene-dosage effects are important, at least for some phenotypes. Therefore, *Nrxn1α+/-* mice may arguably represent a more translationally-relevant model of the 2p16.3 deletions most commonly seen in humans than *Nrxn1α* KO mice, as these are heterozygous in nature. The hyperactive exploratory behaviour seen in male *Nrxn1α+*/- mice may have translational relevance to the hyperactive exploratory behaviour reported in disorders association with 2p16.3 deletion, including ADHD (Garcia Murillo et al., 2015) and ScZ (Perry et al., 2009). The observation that this mild hyperactivity is seen only in males may also have relevance to the increased prevalence of ASD in males. This, along with other recent data on the greater impact of 16p11.2 hemideletion on sleep, learning and brain structure in male as compared to female mice (Angelakos et al., 2017; Grissom et al., 2018; Kumar et al., 2018), supports the suggestion that males may be more sensitive to ASD risk genes and chromosomal variations than females, at least in relation to some disease-relevant phenotypes.

We also identified increased anxiety-like behaviour in *Nrxn1α+/-* mice, as evidenced by a decreased duration spent in the central zone of the arena. One concern is that this could be influenced by the mild hyperlocomotor activity seen selectively in male *Nrxn1α+/-* mice. However, as we found no significant difference in the frequency of entries into the central zone in *Nrxn1α+/-* mice, this suggests that increased locomotor activity is not the primary driver of this observation. This is further supported by the observation that female *Nrxn1α+/-* mice do not show this hyperlocomotor activity, but do spend less time in the central zone of the open field arena. The interpretation that this observation is related to increased anxiety also needs to be made with some caution, particularly in the context of the available published data on the impact of *Nrxn1α*on anxiety-like behaviours. The published data are mixed, with increased anxiety-like behaviour reported in *Nrxn1α-/-* (KO) but not *Nrxn1α+/-* mice in the OFT, elevated plus maze (EPM) and light-dark box (Grayton et al., 2013). By contrast Etherton et al., (1999) found no significant anxiety-like phenotype in the OFT and EPM in *Nrxn1α-/-* (KO) mice, and Dachtler et al., (2015) also found no significant anxiety-like phenotype in *Nrxn1α+/-* mice in these tests. It is likely that differences in animal handling and the experimental protocols used contribute to these differential observations. In addition, differences in sample size are also likely to be relevant, with our study having the largest sample size to date. This suggests that, while our data support a potential increased anxiety-like phenotype in *Nrxn1α+/-* mice, further experimental data is need to more firmly prove this phenotype.

**4.2 mPFC and dorsal raphé metabolism correlate with behavioural alterations present in *Nrxn1a+/-* mice and predict *Nrxn1α* genotype**

Our data indicate that the mPFC is hypoactive and the DRN hyperactive in *Nrxn1α*+/- mice, and that metabolism in these regions, along with that in other regions including the NaS, is useful in predicting *Nrxn1α* genotype. Hypofrontality, decreased PFC function, is seen in multiple neurodevelopmental disorders associated with 2p16.3 deletion, and contributes to executive dysfunction (Hill et al., 2004; Mitelman et al., 2018; Hart et al., 2013; Polyanska et al., 2017). In rodents, the mPFC has an important role in executive functions including attention (Fisher et al., 2020) and cognitive flexibility; in terms of set-shifting (Birrell and Brown, 2000). Thus, *Nrxn1α*+/- mice may model aspects of executive dysfunction in these disorders, and the PFC may be dysfunctional in humans with 2p16.3 deletions. This certainly warrants further systematic investigation.

We found that mPrL metabolism was negatively correlated with LMA in male but not in female mice. Thus, mPrL hypometabolism may contribute to the hypolocomotor phenotype seen selectively in male *Nrxn1α*+/- mice. This suggestion is consistent with data showing that mPFC lesions reduces LMA (Jinks and McGregor, 1997) and that modulating GABAergic (Asinof and Paine, 2013) or serotonergic (Takahashi et al,. 2000) mPFC neurotransmission influences LMA. The cellular and neurochemical basis of the PFC dysfunction seen in *Nrxn1α*+/-mice requires further characterisation. However, we found clear evidence for reduced insulin receptor signalling in the mPFC, which likely contributes to the mPrL hypometabolism present in these animals. Importantly, all of the aforementioned studies implicating the mPFC in the regulation of LMA were conducted in male rodents. As far as we are aware, whether these manipulations impact on LMA in female rodents has not yet been characterised. Our data suggest that these effects may be sex-specific.

mPrL metabolism also correlated with the ability of animals to learn a novel odour discrimination, with lower metabolism associated with better performance (fewer TTC). Therefore, the mPrL hypometabolism seen in *Nrxn1α*+/- mice may relate to their improved ability for novel odour discrimination. The mPrL has a primary role in discriminating between rewarded and non-rewarded environmental cues (Fisher et al., 2020, Sangha et al., 2014), supporting the suggestion that the altered mPrL function seen in *Nrxn1α*+/- mice may contribute to their enhanced performance. As the 14C-2-deoxyglucose signal largely represents the functional activity of synapses (Nudo et al., 1986), whether the hypometabolism seen in the mPFC reflects altered local GABAergic or glutamatergic synaptic neurotransmission would be of interest.

The DRN hypermetabolism identified in *Nrxn1α*+/- mice suggests that serotonergic neurotransmission may be altered. To our knowledge, there are currently no additional published data on the impact of *Nrxn1α* heterozygosity on serotonin system function. However, one post-synaptic binding partner of Nrxn1α, Neuroligin 2 (Nlgn2), impacts on the function of the serotonin system, through direct interaction with the serotonin transporter (Ye et al., 2015). Whether the serotonin system is dysfunctional in *Nrxn1α*+/- mice certainly warrants further investigation, given the reported alterations in serotonin system function in other relevant rodent models (Guo and Commons, 2016), and in order to understand the potential relevance to serotonin system dysfunction in ASD (Muller et al., 2016) and ScZ (Selvraj et al., 2014). Interestingly, there was a positive correlation between DRN metabolism and the latency to make correct choices during the initial odour discrimination phase (Discrimination 1). Therefore, the DRN hypermetabolism seen in *Nrxn1α*+/- mice may relate to their increased correct choice latency. This increased latency suggests that *Nrxn1α*+/- mice may require more time to make correct choices. The potential role of the DRN in this process is consistent with the observation that serotonin regulates behavioural inhibition and impulsivity (Harrison et al., 1999; Worbe et al., 2014). Interestingly, studies using optogenetic stimulation of DRN serotonergic neurons have identified a key role for these neurons in enhancing patience for receiving a reward, with modelling suggesting that DRN activation increases confidence in the future likelihood of receiving a reward (Miyazaki et al., 2018). In addition, a key role for serotonergic neurotransmission in the mPFC has been identified in this process (Miyazaki et al., 2020). Given our observations, the potential contribution of altered serotonin system function in *Nrxn1α*+/- mice to correct choice latency, and the potential impact of *Nrxn1α* heterozygosity on impulsive behaviour and patience, warrants further investigation. In addition, given that we have identified a potential role for reduced insulin receptor signalling in the reduced glucose metabolism seen in the PFC of *Nrxn1α*+/- mice, determining whether altered insulin receptor signalling contributes to the increased DR metabolism seen in these animals also would be of interest.

We found no evidence to suggest that metabolism in the mPrL or DRN correlated with reversal learning performance in mice. This is consistent with published data showing that lesioning the mPrL does not impact on reversal learning (Birrell and Brown, 2000). However, published data support a role for the serotonin system in modulating reversal learning, particularly through its actions in the orbitofrontal cortex (Alsio et al., 2021). We found no evidence for altered orbitofrontal cortex function in *Nrxn1α*+/- mice in this study (supplemental information: Table S2). Further research is needed to understand the neurobiological basis of the reversal learning deficit seen in *Nrxn1α*+/- mice. However, it is important to state that while correlations between regional activity and behaviour can be useful in further understanding the potential neurobiological basis of behavioural deficits in animal models, some deficits are likely to arise from more subtle dysfunction in the interconnectivity of brain networks, and relationships to behaviour might not be apparent when regional metabolism is considered. Thus, future studies characterising the relationship between brain network connectivity and behavioural deficits would be of interest, particularly given the network alterations seen in *Nrxn1a+/-* mice (Hughes et al., 2020).

* 1. **Conclusions**

The data suggest that *Nrxn1a* heterozygosity induces alterations in cognition and behaviour that are relevant to those seen in ASD and other neurodevelopmental disorders associated with 2p16.3 deletion. *Nrxn1α* heterozygosity alters mPFC and DRN function, which may contribute to some of the behavioural alterations observed. Altered mPFC and serotonin system function may be two key mechanisms through which 2p16.3 deletion impacts on cognition, and by which the CNV increases the risk of developing neurodevelopmental disorders. Targeting the PFC and serotonin system may be useful therapeutic strategies for individuals with 2p16.3 deletion and its’ associated neurodevelopmental disorders. Further research is required to more clearly understand the nature of the dysfunction that arises in these systems as a consequence of 2p16.3/*Nrxn1α* heterozygous deletion.

1. **References**

Alsio J., Lehmann O., McKenzie C., Theobald D.E., Searle L., Xia J., *et al*. (2021). Serotonergic innervations of the orbitofrontal and medial-prefrontal cortices are differentially involved in visual discrimination and reversal learning in rats. *Cereb Cortex*, 31, 1090-105. <https://doi.org/10.1093/cercor/bhaa277>.

Angelos C.C., Watson A.J., O’Brien T., Krainock K.S., Nickl-Jockschat T., Abel T. (2017). Hyperactivity and male-specific sleep deficits in the 16p11.2 deletion mouse model of autism. Autism Res, 10, 572-584. <https://doi.org/10.1002/aur.1707>.

Armstrong E.C., Caruso A., Servadio M., Andreae L.C., Trezza V., Scattoni M.L., *et al*. (2020). Assessing the developmental trajectory of mouse models of neurodevelopmental disorders: Social and communication deficits in mice with *Neurexin-1α* deletion. *Genes Brain Behav*, 19, e12630. <https://doi.org/10.1111/gbb.12630>.

Asinof S.K, Paine T.A. (2013). Inhibition of GABA synthesis in the prefrontal cortex increases locomotor activity but does not affect attention in the 5-choice serial reaction time task. *Neuropharmacology,* 65, 39-47. <https://doi.org/10.1016/j.neuropharm.2012.09.009>.

Birrell J.M., Brown V.J. (2000). Medial frontal cortex mediates perceptual attentional set shifting in the rat. *J Neurosci*, 20, 4320-4. <https://doi.org/10.1523/jneurosci.20-11-04320.2000>.

Brambilla P., Cerruti S., Bellani M., Perlini C., Ferro A., Marinelli V., *et al*. (2011). Shared impairment in associative learning in schizophrenia and bipolar disorder. *Prog Neuropsychopharmacol Biol Psychiatry,* 35, 1093-9. <https://doi.org/10.1016/j.pnpbp.2011.03.007>

Braff D.L., Swerdlow N.R., Geyer M.A. (1999). Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. *Am J Psychiatry,* 156, 596-602. <https://doi.org/10.1176/ajp.156.4.596>.

Bussey T.J., Holmes A., Lyon L., Mar A.C., McAllister K.A., Nithianantharajah J., *et al*. (2012). New translational assays for preclinical modelling of cognition in schizophrenia: the touchscreen testing method for mice and rats. *Neuropharmacology,* 62, 1191-203. <https://dx.doi.org/10.1016%2Fj.neuropharm.2011.04.011>.

Castronovo P., Baccarin M., Ricciardello A., Picinelli C., Tomaiuolo P., Cucinotta F., *et al*. (2020). Phenotypic spectrum of *NRXN1* mono- and bi-allelic deficiency: A systematic review. *Clin Genet,* 97, 125-37. <https://doi.org/10.1111/cge.13537>.

Cheng C.H., Chan P.S., Hsu S.C., Liu C.Y. (2018). Meta-analysis of sensorimotor gating in patients with autism spectrum disorders. *Psychiatry Res*. 262: 413-9. <https://doi.org/10.1016/j.psychres.2017.09.016>.

Ching M.S., Shen Y., Tan W.H., Jeste S.S., Morrow E.M., Chen X., *et al*. (2010). Deletions of *NRXN1* (*Neurexin-1*) predispose to a wide spectrum of developmental disorders. *Am J Med Genet B Neuropsychiatr Genet*, 153B, 937-47. <https://doi.org/10.1002/ajmg.b.31063>.

Crawley D., Zhang L., Jones E.J.H., Ahmad J., Oakley B., San Jose Caceres A., *et al*. (2020). Modeling flexible behavior in childhood to adulthood shows age-dependent learning mechanisms and less optimal learning in autism in each age group. *PLoS Biol*, 18, e3000908. <https://doi.org/10.1371/journal.pbio.3000908>.

Dachtler J., Ivorra J.L., Rowland T.E., Lever C., Rodgers R.J., Clapcote S.J. (2015). Heterozygous deletion of *α-neurexin I* or *α-neurexin II* results in behaviors relevant to autism and schizophrenia. *Behav Neurosci*, 129, 765-76. <https://dx.doi.org/10.1037%2Fbne0000108>.

Dawson N., Thompson R.J., McVie A., Thomson D.M., Morris B.J., Pratt J.A. (2012). Modafinil reverses phencyclidine-induced deficits in cognitive flexibility, cerebral metabolism, and functional brain connectivity. *Schizophr Bull*, 38, 457-74. <https://doi.org/10.1093/schbul/sbq090>.

Edmondson D.A., Xia P., McNally Keehn R., Dydak U., Keehn B. (2020). A magnetic resonance spectroscopy study of superior visual search abilities in children with autism spectrum disorder. *Autism Res,* 13, 550-62. <https://doi.org/10.1002/aur.2258>.

Eordegh G., Pertich A., Tarnok Z., Nagy P., Bodosi B., Giricz Z., *et al*. (2020). Impairment of visually guided associative learning in children with Tourette syndrome. *PLoS One* 15, e0234724. <https://doi.org/10.1371/journal.pone.0234724>.

Etherton M.R., Blaiss C.A., Powell C.M., Sudhof T.C. (2009): Mouse *neurexin-1α* deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments. *Proc Natl Acad Sci U S A*, 106, 17998-8003. <https://doi.org/10.1073/pnas.0910297106>.

Fisher B.M., Saksida L.M., Robbins T.W., Bussey T.J. (2020). Functional dissociations between subregions of the medial prefrontal cortex on the rodent touchscreen continuous performance test (rCPT) of attention. *Behav Neurosci*, 134, 1-14. <https://doi.org/10.1037/bne0000338>.

Garcia Murillo L., Cortese S., Anderson D., Di Martino A., Castellanos F.X. (2015). Locomotor activity measures in the diagnosis of attention deficit hyperactivity disorder: Meta-analyses and new findings. *J Neurosci Methods,* 252, 14-26. <https://dx.doi.org/10.1016%2Fj.jneumeth.2015.03.001>.

Grayton H.M., Missler M., Collier D.A., Fernandes C. (2013). Altered social behaviours in *neurexin*-*1α* knockout mice resemble core symptoms in neurodevelopmental disorders. *PLoS One* 8, e67114. <https://doi.org/10.1371/journal.pone.0067114>.

Grissom N.M., McKee S.E., Schoch H., Bowman N., Havekes R., O’Brien W.T., *et al.* (2018). Male-specific deficits in natural reward learning in a mouse model of neurodevelopmental disorders. *Mol Psychiatry*, 23, 544-555. <https://doi.org/10.1038/mp.2017.184>.

Guo Y.-P., Commons K.G. (2016). Serotonin neuron abnormalities in the BTBR mouse model of autism. *Autism Research,* 10: 66-77. <https://doi.org/10.1002/aur.1665>.

Harrison A.A., Everitt B.J., Robbins T.W. (1999). Central serotonin depletion impairs both the acquisition and performance of a symmetrically reinforced go/no-go conditional visual discrimination. *Behav Brain Res*, 100, 99-112. <https://doi.org/10.1016/s0166-4328(98)00117-x>.

Hart H., Radua J., Nakao T., Mataix-Cols D., Rubia K. (2013). Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects. *JAMA Psychiatry*, 70, 185-98. <https://doi.org/10.1001/jamapsychiatry.2013.277>.

Hill K., Mann L., Laws K.R., Stephenson C.M., Nimmo-Smith I., McKenna P.J. (2004). Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. *Acta Psychiatr Scand*, 110, 243-56. <https://doi.org/10.1111/j.1600-0447.2004.00376.x>.

Huang A.Y., Yu D., Davis L.K., Sul J.H., Tsetsos F., Ramensky V., *et al*. (2017): Rare copy number variants in *NRXN1* and *CNTN6* increase risk for Tourette syndrome. *Neuron* 94, 1101-1111. <https://doi.org/10.1016/j.neuron.2017.06.010>.

Hughes R.B., Whittingham-Dowd J., Simmons R.E., Clapcote S.J., Broughton S.J., Dawson N. (2020). Ketamine restores thalamic-prefrontal cortex functional connectivity in a mouse model of neurodevelopmental disorder-associated 2p16.3 deletion. *Cereb Cortex,* 30, 2358-71. <https://doi.org/10.1093/cercor/bhz244>.

Jazbec S., Pantelis C., Robbins T., Weickert T., Weinberger D.R., Goldberg T.E. (2007). Intra-dimensional/extra-dimensional set-shifting performance in schizophrenia: impact of distractors. *Schizophr Res,* 89, 339-49. <https://doi.org/10.1016/j.schres.2006.08.014>.

Jinks A.L., McGregor I.S. (1997). Modulation of anxiety-related behaviours following lesions of the prelimbic or infralimbic cortex in the rat. *Brain Res*, 772, 181-90. <https://doi.org/10.1016/s0006-8993(97)00810-x>.

Kumar V.J., Grissom N.M., McKee S.E., Schoch H., Bowman N., Havekes R., *et al.* (2018). Linking spatial gene expression patterns to sex-specific brain structural changes on a mouse model of 16p11.2 hemideletion. *Transl Psychiatry,* 8, 109. <https://doi.org/10.1038/s41398-018-0157-z>.

Laarakker M.C., Reinders N.R., Bruining H., Ophoff R.A., Kas M.J. (2012). Sex-dependent novelty response in *neurexin-1α* mutant mice. *PLoS One,* 7, e31503. <https://doi.org/10.1371/journal.pone.0031503>.

Lange F., Seer C., Muller-Vahl K., Kopp B. (2017). Cognitive flexibility and its electrophysiological correlates in Gilles de la Tourette syndrome. *Dev Cogn Neurosci*, 27, 78-90. <https://doi.org/10.1016/j.dcn.2017.08.008>.

Manco M., Guerrera S., Rava L., Ciofi Degli Atti M., Di Vara S., Valeri G., *et al*. (2021). Cross-sectional investigation of insulin resistance in youths with autism spectrum disorder. Any role for reduced brain glucose metabolism? *Transl Psychiatry,* 11, 229. <https://doi.org/10.1038/s41398-021-01345-3>.

Marshall C.R., Howrigan D.P., Merico D., Thiruvahindrapuram B., Wu W., Greer D.S., *et al*. (2017). Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. *Nat Genet,* 49, 27-35. <https://doi.org/10.1038/ng.3725>.

Matsunami N., Hadley D., Hensel C.H., Christensen G.B., Kim C., Frackelton E., *et al*. (2013). Identification of rare recurrent copy number variants in high-risk autism families and their prevalence in a large ASD population. *PLoS One,* 8, e52239. <https://doi.org/10.1371/journal.pone.0052239>.

Missler M., Zhang W., Rohlmann A., Kattenstroth G., Hammer R.E., Gottmann K., *et al*. (2003): Alpha-neurexins couple Ca2+ channels to synaptic vesicle exocytosis. *Nature,* 423, 939-48. <https://doi.org/10.1038/nature01755>.

Mitelman S.A., Bralet M.C., Mehmet Haznedar M., Hollander E., Shihabuddin L., Hazlett E.A., *et al*. (2018). Positron emission tomography assessment of cerebral glucose metabolic rates in autism spectrum disorder and schizophrenia. *Brain Imaging Behav*, 12, 532-46. <https://doi.org/10.1007/s11682-017-9721-z>.

Miyazaki K., Miyazaki K.W., Yamanaka A., Tokuda T., Tanaka K.F., Doya K. (2018): Reward probability and timing uncertainty alter the effect of dorsal raphe serotonin neurons on patience. *Nat Commun,* 9, 2048. <https://dx.doi.org/10.1038%2Fs41467-018-04496-y>.

Miyazaki K., Miyazaki K.W., Sivori G., Yamanaka A., Tanaka K.F., Doya K. (2020). Serotonergic projections to the orbitofrontal and medial prefrontal cortices differentially modulate waiting for future rewards. *Sci Adv,* 6, eabc7246. <https://doi.org/10.1126/sciadv.abc7246>.

Muller C.L., Anacker A.M.J., Veenstra-VanderWeele J. (2016). The serotonin system in autism spectrum disorder: From biomarker to animal models. *Neuroscience,* 321, 24-41. <https://doi.org/10.1016/j.neuroscience.2015.11.010>.

Nudo R.J., Masterton R.B. (1986). Stimulation-induced [14C]2-deoxyglucose labeling of synaptic activity in the central auditory system. *J Comp Neurol,* 245, 553-65. <https://doi.org/10.1002/cne.902450410>.

Openshaw R.L., Thomson D.M., Thompson R., Penninger J.M., Pratt J.A., Morris B.J., *et al.* (2020). *Map2k7* haploinsufficiency induces brain imaging endophenotypes and behavioral phenotypes relevant to schizophrenia. *Schizophr Bull*, 46, 211-23. <https://doi.org/10.1093/schbul/sbz044>.

O'Riordan M., Passetti F.. (2006). Discrimination in autism within different sensory modalities. *J Autism Dev Disord*, 36, 665-75. <https://doi.org/10.1007/s10803-006-0106-1>.

Paxinos G, Franklin KBJ. 2001. The mouse brain in stereotaxic coordinates. 2nd ed. London, UK: Academic Press.

Pedregosa F., Varoquaux G., Gramfort A., Michel V., Thirion B., Grisel O., *et al*. (2011). Scikit-learn: Machine learning in Python. *J Mach Learn Res,* 12, 2825-30.

Perry W., Minassian A., Paulus M.P., Young J.W., Kincaid M.J., Ferguson E.J., *et al*. (2009). A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. *Arch Gen Psychiatry,* 66, 1072-80. <https://dx.doi.org/10.1001%2Farchgenpsychiatry.2009.58>.

Plaisted K., O'Riordan M., Baron-Cohen S. (1998). Enhanced discrimination of novel, highly similar stimuli by adults with autism during a perceptual learning task. *J Child Psychol Psychiatry,* 39, 765-75.

Polyanska L., Critchley H.D., Rae C.L. (2017). Centrality of prefrontal and motor preparation cortices to Tourette Syndrome revealed by meta-analysis of task-based neuroimaging studies. *Neuroimage Clin,* 16, 257-67. <https://doi.org/10.1016/j.nicl.2017.08.004>.

Reddy L.F., Waltz J.A., Green M.F., Wynn J.K., Horan W.P. (2016). Probabilistic reversal learning in schizophrenia: Stability of deficits and potential causal mechanisms. *Schizophr Bull*, 42, 942-51. <https://doi.org/10.1093/schbul/sbv226>.

Reichelt A.C., Rodgers R.J., Clapcote S.J. (2012). The role of neurexins in schizophrenia and autistic spectrum disorder. *Neuropharmacology,* 62, 1519-26. <https://doi.org/10.1016/j.neuropharm.2011.01.024>.

Sangha S., Robinson P.D., Greba Q., Davies D.A., Howland J.G. (2014). Alterations in reward, fear and safety cue discrimination after inactivation of the rat prelimbic and infralimbic cortices. *Neuropsychopharmacology,* 39, 2405-13. <https://doi.org/10.1038/npp.2014.89>.

Schaaf C.P., Boone P.M., Sampath S., Williams C., Bader P.I., Mueller J.M., *et al*. (2012). Phenotypic spectrum and genotype-phenotype correlations of *NRXN1* exon deletions. *Eur J Hum Genet,* 20, 1240-7. <https://doi.org/10.1038/ejhg.2012.95>.

Schlagenhauf F., Huys Q.J., Deserno L., Rapp M.A., Beck A., Heinze H.J., *et al*. (2014). Striatal dysfunction during reversal learning in unmedicated schizophrenia patients. *Neuroimage,* 89, 171-80. <https://doi.org/10.1016/j.neuroimage.2013.11.034>.

Selvaraj S., Arnone D., Cappai A., Howes O. (2014). Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. *Neurosci Biobehav Rev,* 45, 233-45. <https://doi.org/10.1016/j.neubiorev.2014.06.005>.

Shephard E., Jackson G.M., Groom M.J. (2016). Electrophysiological correlates of reinforcement learning in young people with Tourette syndrome with and without co-occurring ADHD symptoms. *Int J Dev Neurosci,* 51, 17-27. <https://doi.org/10.1016/j.ijdevneu.2016.04.005>.

Swerdlow N.R., Karban B., Ploum Y., Sharp R., Geyer M.A., Eastvold A. (2001). Tactile prepuff inhibition of startle in children with Tourette's syndrome: in search of an "fMRI-friendly" startle paradigm. *Biol Psychiatry,* 50, 578-85. <https://doi.org/10.1016/s0006-3223(01)01164-7>.

Takahashi H., Takada Y., Nagai N., Urano T., Takada A. (2000). Serotonergic neurons projecting to hippocampus activate locomotion. *Brain Res,* 869, 194-202. <https://doi.org/10.1016/s0006-8993(00)02385-4>.

Tanaka S., Young J.W., Gresack J.E., Geyer M.A., Risbrough V.B. (2011). Factor analysis of attentional set-shifting performance in young and aged mice. *Behav Brain Funct,* 7, 33. <https://doi.org/10.1186/1744-9081-7-33>.

Ullman-Cullere M.H., Foltz C.J. (1999). Body condition scoring: a rapid and accurate method for assessing health status in mice. *Lab Anim Sci,* 49, 319-23.

Wang J., Gong J., Chen Y., Liu L., Gu H., Luo H., et al. (2017). Neurexin gene family variants for autism spectrum disorder. *Autism Research,* 11, 37-43. <https://doi.org/10.1002/aur.1881>

Worbe Y., Savulich G., Voon V., Fernandez-Egea E., Robbins T.W. (2014). Serotonin depletion induces 'waiting impulsivity' on the human four-choice serial reaction time task: cross-species translational significance. *Neuropsychopharmacology,* 39, 1519-26. <https://doi.org/10.1038/npp.2013.351>.

Ye R., Quinlan M.A., Iwamoto H., Wu H.H., Green N.H., Jetter C.S., *et al*. (2015). Physical interactions and functional relationships of Neuroligin 2 and midbrain serotonin transporters. *Front Synaptic Neurosci,* 7, 20. <https://doi.org/10.3389/fnsyn.2015.00020>.

Yuen R.K.C., Merico D., Bookman M., Howe J.L., Thiruvahindrapuram B., Patel R.V., *et al*. (2017). Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder. *Nat Neurosci,* 20, 602-11. <https://doi.org/10.1038/nn.4524>.

Young J.W., Powell S.B., Geyer M.A., Jeste D.V., Risbrough V.B. (2010). The mouse attentional-set-shifting task: a method for assaying successful cognitive aging? *Cogn Affect Behav Neurosci,* 10, 243-51. <https://doi.org/10.3758/cabn.10.2.243>.

Westwood H., Stahl D., Mandy W., Tchanturia K. (2016). The set-shifting profiles of anorexia nervosa and autism spectrum disorder using the Wisconsin Card Sorting Test: a systematic review and meta-analysis. *Psychol Med,* 46, 1809-27. <https://doi.org/10.1017/s0033291716000581>.

Zhao Z., Ksiezak-Reding H., Riggio S., Haroutunian V., Pasinetti G.M. (2006). Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. *Schizophr Res,* 84, 1-14. <https://doi.org/10.1016/j.schres.2006.02.009>.

**Figure Legends**

**Figure 1. Nrxn1α+/− mice show altered anxiety-like behaviour and locomotor activity in the open-field test (OFT).** Nrxn1α+/− mice show **(A)** reduced time spent in the central zone (secs) but not an altered **(D)** frequency of movement into the central zone of the open field arena. Male, but not female, Nrxn1α+/− mice show hyperactivity in the open field as evidenced by increased **(B, C)** distance moved (cm) and **(E, F)** movement duration (secs). Data shown as Mean ± S.E.M over the 15 minute recording duration (60 second time bins). \*P<0.05 and \*\*\*P<0.001 genotype effect (repeated measures ANOVA). Group sizes were WT: *n*=36 (male, *n*=18) and Nrxn1α+/−: *n*=33 (male, *n*=15).WT = wild-type and *Nrxn1α* Hz = *Nrxn1α+/-* mice.

**Figure 2. Nrxn1α+/− mice show enhanced learning of a novel odour-reward discrimination but impaired reversal learning.** Nrxn1α+/− mice show a reduced number of trials to reach criteria (TTC) during the **(A)** initial (Discrimination 1) but not **(B)** second (Discrimination 2) odour-reward discrimination phase. **(C)** Nrxn1α+/− mice require an increased number of TTC during the reversal-learning stage. Nrxn1α+/− mice show an increased latency to make correct, but not incorrect, responses during the **(D)** initial discrimination (Discrimination 1) and **(E)** second discrimination (Discrimination 2). Nrxn1α+/− mice do not show an altered sensitivity to punishment for making incorrect choices during the reversal phase, as shown by the **(F)** correction ratio. Data shown as violin plots. \*P<0.05 difference from WT (ANOVA). Group sizes were WT: n=29 (male, n=16) and *Nrxn1α+/−*: n=26 (male, n=13). WT = wild-type and *Nrxn1α* Hz = *Nrxn1α+/-* mice.

**Figure 3. Metabolism in the mPrL, DRN and NaS predicts *Nrxn1α* genotype classification and insulin receptor signalling is decreased in the PFC of Nrxn1α+/− mice.** Nrxn1α+/− mice show significant **(A)** hypometabolism in the medial prelimbic cortex (mPrL) with a contrasting **(B)** hypermetabolism in the dorsal raphé (DRN). \*\*P<0.05, \*\*\*P<0.01 significant difference from WT (ANOVA). **(C)** Insulin receptor (IRβ) protein levels**, (D)** activated insulin receptor levels (pIR) and **(E)** the ratio between pIR:IRβ are significantly decreasedin the PFC of Nrxn1α+/− mice. \*P<0.05 difference from WT (Wilcoxon). Inset blot images show **(C)** representative IRβ bands, **(D)** representative pIR bands, and **(E)** total protein levels for the same lanes. CART decision tree classification predicts *Nrxn1α* genotype on the basis of metabolism in the mPrL, DRN and NaS. The two most common decision tree structures generated during LOOCV are shown, with the decision tree structure in **(F)** being present in 21% of the models generated and **(G)** being present in 18%. Full details of the other LOOCV models generated are shown in the supplemental information. Group sizes were WT: n = 19 (male, n = 9) and *Nrxn1α+/−*: n = 20 (male, n=10). WT = wild-type and *Nrxn1α* Hz = *Nrxn1α+/-* mice.

**Figure 4. Metabolism in the mPrL and DRN correlate with behaviours altered in Nrxn1α+/− mice.** Cerebral metabolism in the mPrL negatively correlates with locomotor activity measures, including **(A, B)** velocity and **(C, D)** movement duration (secs) in male, but not infemale, mice. **(E)** Cerebral metabolism in the mPrL positively correlates with trials to criteria (TTC) in the initial discrimination (Discrimination 1) phase of the OB-DaRL task, in mice of both sexes. **(F)** Cerebral metabolism in the DRN positively correlates with correct choice trial latency in the initial discrimination (Discrimination 1) phase of the task, in mice of both sexes. Full data are shown in the supplemental information (Tables S3 and S4). Group sizes were WT: n = 19 (male, n = 9) and Nrxn1α+/−: n = 20 (male, n = 10). WT = wild-type and *Nrxn1α* Hz = *Nrxn1α+/-* mice.

**Figure 1**




**Figure 2**

**Figure 3**

****

**Figure 4**

****